CS
THRX

Credit Suisse’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Credit Suisse’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$5 – 3846
2022
Q4 		$5 Sell
1
-93
-99% -$545 ﹤0.01% 3831
2022
Q3 		$1K Buy
94
+80
+571% +$565 ﹤0.01% 3975
2022
Q2 		$0 Buy
+14
New +$116 ﹤0.01% 4462

Other funds holding THRX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Credit Suisse's THRX Position: Q1 2023 in Review

Credit Suisse sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2023, closing a stake of 1 share — an estimated $5 sold.

Credit Suisse first reported a position in THRX in Q2 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 72 funds tracked by Wall St. Rank hold THRX as of Q1 2023.

  • Credit Suisse reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 1 Theseus Pharmaceuticals, Inc. Common Stock share in Q1 2023, an estimated $5.
  • Credit Suisse first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • Credit Suisse's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $1K in Q3 2022.
  • 72 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.